AGN is up 6% in early trading based on solid 2Q10 results. In spite of FDA approval today of a Botox competitor for cervical dystonia (#msg-52866968), AGN’s share price is within striking distance of its all-time high of $70.40 reached in early 2008.
Perhaps you’ve been unduly bearish on this company.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.